Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592867 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL19385435 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL11694103 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4514648 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4517239 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1784070 | 1.00 | — | — | |
| SCHEMBL8139520 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4219652 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL597810 | 1.00 | — | — | |
| SCHEMBL842302 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717019-B | Continuous flow reaction method for asymmetric allyl alkylation reaction | 哈尔滨工业大学（深圳） | 2024-12-31 | — | — | CN | claimed |
| CN-115583863-B | Asymmetric allyl alkylation reaction method | 哈尔滨工业大学（深圳） | 2023-10-31 | — | — | CN | claimed |
| CN-115583863-A | Method for asymmetric allyl alkylation reaction | 哈尔滨工业大学（深圳） | 2023-01-10 | — | — | CN | claimed |
| CN-113717019-A | Continuous flow reaction method for asymmetric allyl alkylation reaction | 哈尔滨工业大学（深圳） | 2021-11-30 | — | — | CN | claimed |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12508226-B2 | Lipid composition | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20250249123-A1 | LIPIDS AND COMPOSITIONS THEREOF | GENERATION BIO CO. | 2025-08-07 | — | — | US | disclosed |
| US-12370143-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4328309-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12285525-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-04-29 | — | — | US | disclosed |
| US-12263228-B2 | Lipids and compositions thereof | GENERATION BIO CO. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-116172975-B | Lipid particle, nucleic acid drug comprising same, and composition for nucleic acid delivery | 富士胶片株式会社 | 2025-03-28 | — | — | CN | disclosed |
| WO-1992019610-A1 | 2- AND 5-ALKYL AND PHENYL SUBSTITUTED 4-(1-HYDROXY, 1-ACYLOXY OR 1-CARBAMOYLOXY)-5-HYDROXY-2(5H)-FURANONES AS ANTI-INFLAMMATORY AGENTS | ALLERGAN, INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5082954-A | Intermediates and processes for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents | ALLERGAN, INC. (US) | 1992-01-21 | — | — | US | disclosed |
| US-5045564-A | Calcium channel antagonists | ALLERGAN, INC. (US) | 1991-09-03 | — | — | US | disclosed |
| US-5013850-A | 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents | ALLERGAN, INC. (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0372940-A2 | Anti-inflammatory 2-furanones | ALLERGAN, INC (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4611071-A | Metal alkyl process | ETHYL CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4507241-A | Method for the hydrocarbylation of naphthoquinone derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
| US-4065444-A | LOW TEMPERATURE IMPACT STRENGTH | UNIROYAL, INC. (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370143-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | TSHR 999/4885THRB 2183/4885DNM1 1564/4885 |
| US-12285525-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | TSHR 999/4885THRB 2183/4885DNM1 1564/4885 |
| US-12263228-B2 | Lipids and compositions thereof | C1R, LIPG, LRBA | TSHR 2035/4885THRB 1569/4885DNM1 1428/4885 |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | LDLR, NR1H3, NR1H2 | TSHR 1103/4885THRB 1305/4885DNM1 1101/4885 |
| US-20250249123-A1 | LIPIDS AND COMPOSITIONS THEREOF | C1R, LIPG, LRBA | TSHR 2035/4885THRB 1569/4885DNM1 1428/4885 |
| US-12508226-B2 | Lipid composition | APOB, NAF1, SLC27A1 | TSHR 1216/4885THRB 1398/4885DNM1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.